Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. immune recognition
Show results for
Products

Companies

News
Articles

Refine by
Date

  • Older

Immune Recognition Articles & Analysis

7 news found

Creative BioMart Enhances Epitope Mapping Services to Support Antibody and Vaccine Development

Creative BioMart Enhances Epitope Mapping Services to Support Antibody and Vaccine Development

Epitope mapping is a fundamental tool in immunology and molecular biology, used to pinpoint the characterizing monoclonal antibodies, guiding vaccine formulation, and understanding immune recognition. It also plays a key role in optimizing antibody affinity, minimizing cross-reactivity, and evaluating the functional impact of epitope location on therapeutic ...

ByCreative BioMart


Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

“With the proteolytic shedding of the α1 and α2 domains of MICA/B being recognized as a common tumor escape mechanism, we are encouraged that our novel CAR design, which uniquely targets the α3 domain of MICA/B, has shown the potential to overcome shedding and restore NK and T cell-mediated tumor immunity. We look forward to treating patients with FT536 as ...

ByFate Therapeutics, Inc.


GI Innovation enters into clinical collaboration with AstraZeneca to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy

GI Innovation enters into clinical collaboration with AstraZeneca to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy

For example, some patients with small cell lung cancer, gastric/gastroesophageal junction cancer, biliary tract cancer and triple-negative breast cancer are resistant to conventional checkpoint inhibitor monotherapy, as their low immune infiltrates or lack of antigen recognition prevent them from properly respond to the therapy. ...

ByGI Innovation


Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition

Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition

AMICA is a downloadable database of annotated multi-omic immune cells that includes information about gene expression, proteins, T-cell and B-cell receptors for immune cells, clinical and/or lab data, and a downloadable artificial intelligence software platform designed for characterizing and analyzing immune cells, as well as analyzing the ...

ByImmunai


ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

The combination of ParvOryx with bevacizumab, an anti-angiogenic antibody, or nivolumab, an immune checkpoint inhibitor, showed synergistic effects compared to the single agents in the explant model system. ...

ByORYX GmbH & Co. KG


ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

Moreover, in a follow-up program in patients with recurrent glioblastoma, metastatic colorectal cancer and NSCLC, the enhancement of efficacy of ParvOryx in combination with immune modulators like bevacizumab alone or together with immune checkpoint inhibitors was investigated. ...

ByORYX GmbH & Co. KG


ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

Secondary endpoints included anti-tumor effects and cellular immune response, plus overall survival. To identify immunological and molecular signatures of responses, three serial liver biopsies (before, during, and after virotherapy) allowed for in-depth analyses of pathological tumor characteristics, tumor-infiltrating immune cells, quantification of cytokines ...

ByORYX GmbH & Co. KG

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT